The portfolio manager is a fellowship-trained orthopaedic spine surgeon and Chief of Orthopaedic Spine Surgery, bringing a dual lens of clinical domain expertise and rigorous business training to long-duration equity investing.

The combination of an MD, MBA, and a decade of spine surgery and medtech consulting provides genuine informational advantages in evaluating healthcare and pharmaceutical franchises — particularly in metabolic disease treatment, life sciences software, and medical device economics — while the broader investment framework applies a Buffett-style discipline to permanent moats across all sectors globally.

Duramen Capital was formally constituted in May 2026 with a signed Investment Policy Statement, operating documentation, and written position thesis memos for all initial holdings — all completed and dated before the first dollar was deployed. The analytical process existed before the performance record.

The fund's investment universe spans global listed equities across the US, Europe, and Asia, with a particular emphasis on businesses operating in regulated, compliance-driven industries where switching costs are structural rather than merely commercial — and where the portfolio manager's clinical and consulting background provides a meaningful edge in evaluating franchise durability.